Peginterferon beta-1a

From WikiProjectMed
Jump to navigation Jump to search
Peginterferon beta-1a
Names
Trade namesPlegridy, Plegridy Pen
  • 1-Ether with N-(3-hydroxy-2-methylpropyl)interferon β-1a (human) α-methyl-ω-hydroxy-poly(oxy-1,2-ethanediyl)
Clinical data
Drug classImmunomodulator[1]
Main usesMultiple sclerosis[1]
Side effectsHeadache, muscle pain, flu-like symptoms, fever, weakness, redness, pain or itching at the injection site[2]
Pregnancy
category
  • AU: D[3]
  • US: C (Risk not ruled out)[3]
Routes of
use		Subcutaneous injection
Typical dose125 ucg[4]
External links
AHFS/Drugs.comMonograph
MedlinePlusa614059
Legal
License data
Legal status
  • US: ℞-only [4]
  • EU: Rx-only [2]
  • In general: ℞ (Prescription only)
Chemical and physical data
FormulaC913H1417N246O256PS7 [C2H4O]n
Molar mass44 000 g·mol−1

Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.[1] It is specifically used for the relapsing forms including clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease.[4] It is given by injection under the skin.[1]

Common side effects include headache, muscle pain, flu-like symptoms, fever, weakness, and redness, pain or itching at the injection site.[2] Other side effects may include liver problems, depression, seizures, heart failure, and anaphylaxis.[1] There are concerns with use in pregnancy.[5] How it works is not entirely clear; however it is believed to suppress the immune system.[2] It is made from interferon beta-1a joined with polyethylene glycol.[2]

Peginterferon beta-1a was approved for medical use in the United States and Europe in 2014.[2][1] In the United States it costs about 7,500 USD for 4 weeks of medication as of 2021.[6] This amount in the United Kingdom costs the NHS about £650.[7]

Medical uses

In the United States peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[4]

In the European Union peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.[2]

Dosage

It is given at a dose of 125 ucg every two weeks.[4] A smaller dose of 94 ucg may be used for the first two shots.[4]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Peginterferon Beta-1a Monograph for Professionals". Drugs.com. Archived from the original on 5 March 2021. Retrieved 27 October 2021.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Plegridy EPAR". European Medicines Agency (EMA). Archived from the original on 26 June 2020. Retrieved 24 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ↑ 3.0 3.1 "Peginterferon beta-1a (Plegridy) Use During Pregnancy". Drugs.com. 22 July 2019. Archived from the original on 26 June 2020. Retrieved 25 June 2020.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 "Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution". DailyMed. 30 March 2020. Archived from the original on 26 June 2020. Retrieved 25 June 2020.
  5. ↑ "Peginterferon beta-1a (Plegridy) Use During Pregnancy". Drugs.com. Archived from the original on 26 June 2020. Retrieved 27 October 2021.
  6. ↑ "Plegridy Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 21 April 2021. Retrieved 27 October 2021.
  7. ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 897. ISBN 978-0857114105.

External links

Identifiers:
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Peginterferon_beta-1a&oldid=1380634"